Remarkably, knocking out the A2A adenosine receptor in mice produced a similar enhancement of anti-tumor immunity, and in both cases (CAF treatment or A2A gene deletion), the outcome was tumor growth suppression or rejection. The gene discussed is ADORA2A; the disease is neoplasm.